These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12714797)

  • 21. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment.
    Devanand DP; Pelton GH; Zamora D; Liu X; Tabert MH; Goodkind M; Scarmeas N; Braun I; Stern Y; Mayeux R
    Arch Neurol; 2005 Jun; 62(6):975-80. PubMed ID: 15956169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
    Han HJ; Kim BC; Lee JY; Ryu SH; Na HR; Yoon SJ; Park HY; Shin JH; Cho SJ; Yi HA; Choi MS; Heo JH; Park KW; Kim KK; Choi SH
    Dement Geriatr Cogn Disord; 2012; 34(3-4):167-73. PubMed ID: 23051684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype.
    Gabryelewicz T; Religa D; Styczynska M; Peplonska B; Pfeffer A; Wasiak B; Luczywek E; Golebiowski M; Androsiuk W; Czyzewski K; Przekop I; Barcikowska M
    Dement Geriatr Cogn Disord; 2002; 14(4):208-12. PubMed ID: 12411763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
    Rafii MS; Walsh S; Little JT; Behan K; Reynolds B; Ward C; Jin S; Thomas R; Aisen PS;
    Neurology; 2011 Apr; 76(16):1389-94. PubMed ID: 21502597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease.
    Blesa R; Aguilar M; Casanova JP; Boada M; Martínez S; Alom J; de la Hoz CH; Sancho J; Fernández O; Gil-Neciga E; Massó JF
    Alzheimer Dis Assoc Disord; 2006; 20(4):248-54. PubMed ID: 17132969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease.
    Alafuzoff I; Helisalmi S; Heinonen EH; Reinikainen K; Hallikainen M; Soininen H; Koivisto K
    Eur J Clin Pharmacol; 2000; 55(11-12):815-9. PubMed ID: 10805059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
    Farlow M; Lane R; Kudaravalli S; He Y
    Pharmacogenomics J; 2004; 4(5):332-5. PubMed ID: 15289797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
    Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
    Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.
    Rigaud AS; Traykov L; Caputo L; Guelfi MC; Latour F; Couderc R; Moulin F; de Rotrou J; Forette F; Boller F
    Eur J Neurol; 2000 May; 7(3):255-8. PubMed ID: 10886308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease: clinical implications of the apolipoprotein E genotype.
    Farlow MR
    Neurology; 1997 May; 48(5 Suppl 6):S30-4. PubMed ID: 9153158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of the susceptibility genes apolipoprotein E-epsilon 4 and apolipoprotein E-epsilon 2 on the rate of disease expressivity of late-onset Alzheimer's disease.
    Roses AD; Saunders AM; Corder EH; Pericak-Vance MA; Han SH; Einstein G; Hulette C; Schmechel DE; Holsti M; Huang D
    Arzneimittelforschung; 1995 Mar; 45(3A):413-7. PubMed ID: 7763336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of the apolipoprotein E type 4 allele on cerebral glucose metabolism in Alzheimer's disease patients.
    Lee KU; Lee JS; Kim KW; Jhoo JH; Lee DY; Yoon JC; Lee JH; Lee DS; Lee MC; Woo JI
    J Neuropsychiatry Clin Neurosci; 2003; 15(1):78-83. PubMed ID: 12556576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. APOE2 and consanguinity: a risky combination for Alzheimer's disease.
    Kaur M; Balgir PP
    J Alzheimers Dis; 2005 Dec; 8(3):293-7. PubMed ID: 16340087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology.
    Baum L; Chen L; Ng HK; Pang CP
    Microsc Res Tech; 2000 Aug; 50(4):278-81. PubMed ID: 10936880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease.
    Gomez-Isla T; West HL; Rebeck GW; Harr SD; Growdon JH; Locascio JJ; Perls TT; Lipsitz LA; Hyman BT
    Ann Neurol; 1996 Jan; 39(1):62-70. PubMed ID: 8572669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.